Study S001860

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan: Amendment 1 to Study Protocol and Statistical Analysis Plan (PDF)Study Protocol and Informed Consent Form: Study Protocol and Statistical Analysis Plan (PDF)Study Protocol and Statistical Analysis Plan: Amendment 2 to Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT07088718
Acronym: DUP-SURPASS
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 44671
Start: 2024-10-01
Primary completion: 2025-07-30
Lead sponsor: Brigham and Women's Hospital
Conditions: Type 2 Diabetes; Major Adverse Cardiac Events; Cardiovascular (CV) Risk
Interventions: DRUG:Tirzepatide; DRUG:Dulaglutide
Results posted: FALSE

Registered primary outcomes

First occurence of MACE (all-cause mortailty, myocardial infarction, or death) [1 day after cohort entry date until the first of outcome or censoring, up to 365 days]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007550	Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Krüger N, Nature medicine	2026	Randomized trial	PMID 41207920 DOI	cites ClinicalTrials.gov:NCT07088718; registry reference DERIVED:41207920